Clinical Trial Update: Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports long-term safety data for SPA100, a fixed-dose combination of aliskiren and amlodipine, in adults with essential hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)
• Amlodipine (amlodipine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED